Abstract 14103: Lipoprotein (a) is an Important Factor to Determine Myocardial Viability and Left Ventricular Functional Recovery After Acute Myocardial Infarction
Introduction: High serum levels of lipoprotein (a) (Lp(a)) are associated with adverse outcomes after acute myocardial infarction (AMI). Lp(a) exerts its atherogenic and thrombogenic properties, which suggests greater lipid component of plaque and thrombi at the culprit lesion of AMI with elevated Lp(a). The risk of coronary artery disease is increased with a threshold serum Lp(a) level of 25 mg/dl.
Purpose: We sought to evaluate impact of Lp(a) on myocardial viability and left ventricular function after AMI.
Methods: The study included 156 patients (66±10.7 yrs, mean±sd, men 122, LAD/LCX/RCA 80/16/60) with first AMI within 24 hours from the onset who underwent emergent PCI. Serum Lp(a) was measured at admission. Serum CPK values were measured at admission and at intervals of 4 hours. Peak CPK value was determined. Within 2 weeks, Tl/BMIPP SPECT was performed to measure perfusion-metabolism mismatch score, an indicator of viable myocardium, from each total defect score of Tl/BMIPP using 17-segment model and semiquantitative visual score (0:normal, to 4:no uptake). Left ventricular ejection fraction (LVEF) was measured by two-dimensional echocardiography (2D trace) within 1 week (baseline LVEF) and at 6 months to 1 year (follow-up LVEF).
Results: The study patients were divided into the group with serum Lp(a)≧25mg/dl at admission (n=42, Lp(a) 44.0±19.4mg/dl) and the group with Lp(a)<25 (n=114, Lp(a) 10.8±6.5). There were no significant differences between the two groups with respect to age, gender, peak CPK (2732±2060 IU/L (Lp(a)≧25), 2971±2254 (Lp(a)<25)). The mismatch score was significantly lower in Lp(a)≧25 group than in Lp(a)<25 (4.4±3.3 vs 5.9±3.9, p<0.05, respectively). Δ%LVEF (100*(follow-up LVEF - baseline LVEF)/ baseline LVEF) was significantly lower in Lp(a)≧25 than Lp(a)<25 (-2.0±11.0 vs 7.4±13.0, p<0.05, respectively).
Conclusions: Elevated Lp(a) was associated with less myocardial viability and less LVEF recovery after AMI.
Author Disclosures: K. Hayasaka: None. H. Hikita: None. T. Shigeta: None. T. Misawa: None. T. Mizusawa: None. Y. Yamakami: None. K. Kojima: None. Y. Sagawa: None. H. Ohtani: None. K. Hishikari: None. K. Yamao: None. E. Nakashima: None. T. Sugiyama: None. J. Nakajima: None. M. Takigawa: None. Y. Tanaka: None. K. Ohkubo: None. S. Kimura: None. K. Takagi: None. T. Kuwahara: None. A. Takahashi: None. M. Isobe: None.
- © 2015 by American Heart Association, Inc.